Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-Blind, double-Dummy, Parallel-Controlled study with a 6-week duration.
- Trial name
- NCT07741331
- Testing
- KH607 tablets, Vortioxetine Hydrobromide Tablets, Part B: KH607
- Volunteers
- 326 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Depressive Disorder
A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
The purpose of this study is to compare the tolerability and efficacy of different doses of duloxetine in patients with major depressive disorder.
- Trial name
- NCT00191061
- Testing
- duloxetine hydrochloride
- Where
- 32 sites in United States
- Volunteers
- 640 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder
SPL026 With or Without SSRIs in Participants With MDD
The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor…
- Trial name
- NCT05553691
- Testing
- SPL026
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Small Pharma Ltd
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042562
- Testing
- duloxetine
- Where
- 23 sites in United States
- Sponsor
- Eli Lilly and Company
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer…
- Trial name
- NCT01752608
- Testing
- eCBT Mood
- Where
- 2 sites in United States
- Sponsor
- MindApps
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
- Trial name
- NCT01034462
- Testing
- Levomilnacipran ER
- Where
- 23 sites in United States
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Major Depressive Disorder Study In Adults
A study to obtain safety and tolerability data
- Trial name
- NCT00049972
- Testing
- paroxetine CR
- Where
- 71 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing…
- Trial name
- NCT01437657
- Testing
- RO4917523 0.5 mg, RO4917523 1.5 mg
- Where
- 76 sites in United States, Chile and 7 more
- Volunteers
- 319 people
- Sponsor
- Hoffmann-La Roche
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Depression, Cognition
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder
- Trial name
- NCT00062673
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive…
- Trial name
- NCT04513912
- Testing
- Seltorexant, Quetiapine XR
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 757 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110902
- Testing
- Agomelatine (AGO178C)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 589 people
- Sponsor
- Novartis Pharmaceuticals